Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce - Summary - MDSpire

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce

  • By

  • Paolo Manzoni

  • Eugenio Baraldi

  • Fabio Midulla

  • Olivier Claris

  • Sandro Dessardo

  • Terho Heikkinen

  • Richard Thwaites

  • Bosco Paes

  • Xavier Carbonell-Estrany

  • Dmytro Dobryanskyy

  • Merih Cetinkaya

  • Adel S Al Harbi

  • Ji-Man Kang

  • Anne Goh Eng Neo

  • Hsin Chi

  • Guilherme Sant’Anna

  • Mónica Villa Guillén

  • Gonzalo Luis Mariani

  • Marco Aurelio Palazzi Safadi

  • Soledad Urzua

  • Heather J Zar

  • Pierre Goussard

  • Barry Rodgers-Gray

  • Nicola Waghorne

  • Manuel Sanchez Luna

  • July 2, 2025

  • 0 min

Share

Objective:

To develop consensus recommendations for the use of long-acting monoclonal antibodies (LAmAbs) for RSV disease prevention in children.

Key Findings:
  • LAmAbs are recommended for all infants <8 months without maternal RSV vaccination, preterm infants <12 months, and children <24 months with high-risk conditions.
  • Seasonal administration of LAmAbs is recommended, with local decisions in endemic regions regarding year-round use.
  • LAmAbs have shown high efficacy, effectiveness, and cost-effectiveness in preventing RSV disease.
Interpretation:

The recommendations provide a framework for global guidelines on LAmAbs use, emphasizing the need for equitable access, especially in low- and middle-income countries.

Limitations:
  • Affordability and access to LAmAbs in low- and middle-income countries remain significant challenges.
  • Further research is needed on LAmAbs effectiveness in children with underlying medical conditions.
Conclusion:

The ARMADA Taskforce strongly endorses the implementation of LAmAb programs to reduce the burden of RSV disease in infants and young children globally.

Original Source(s)

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce

  • by Paolo Manzoni, Eugenio Baraldi, Fabio Midulla, Olivier Claris, Sandro Dessardo, Terho Heikkinen, Richard Thwaites, Bosco Paes, Xavier Carbonell-Estrany, Dmytro Dobryanskyy, Merih Cetinkaya, Adel S Al Harbi, Ji-Man Kang, Anne Goh Eng Neo, Hsin Chi, Guilherme Sant’Anna, Mónica Villa Guillén, Gonzalo Luis Mariani, Marco Aurelio Palazzi Safadi, Soledad Urzua, Heather J Zar, Pierre Goussard, Barry Rodgers-Gray, Nicola Waghorne, Manuel Sanchez Luna

  • July 2, 2025

Related Content

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Hydrocortisone May Lower Severe CAP Mortality

Network meta-analysis suggests hydrocortisone may offer mortality and ventilation benefits, although evidence certainty remained low.

Not All Lung Bacteria Are the Enemy

Cross-disease meta-analysis also found modest associations with lung function, though findings varied by disease type